RegenLab USA, Inc. (RGNA)

RegenLab USA will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

RegenLab USA Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	54.26	49.17	48.38
Revenue Growth	-	1.63%	-
Cost of Revenue	-	14.93	13.91
Gross Profit	37.49	34.24	34.47
Selling, General & Admin	-	27.08	26.76
Research & Development	-	6.49	4.24
Operating Expenses	-	33.56	30.99
Operating Income	3.54	0.68	3.48
Interest Expense (Income)	3.73	0.22	0.81
Other Expense (Income)	1.07	1.35	-0.14
Pretax Income	-1.27	-0.9	2.81
Income Tax	-0.13	0.35	0.5
Net Income	-1.14	-1.24	2.31

Additional Metrics

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	2.8	-2.11	1.28
Free Cash Flow Growth	-	-	-
Gross Margin	69.08%	69.63%	71.24%
Operating Margin	6.53%	1.37%	7.19%
Profit Margin	-2.10%	-2.52%	4.78%
Free Cash Flow Margin	5.16%	-4.30%	2.64%
Effective Tax Rate	-	-	17.63%
EBITDA	3.55	0.21	6.6
EBITDA Margin	6.55%	0.42%	13.63%
Depreciation & Amortization	1.09	0.88	2.98
EBIT	2.47	-0.68	3.62
EBIT Margin	4.55%	-1.38%	7.47%